Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease

Millie D. Long; Corey A. Siegel; Bincy P. Abraham; Michael Chiorean; Uma Mahadevan

doi:10.1016/j.cgh.2021.02.003

Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease

Millie D. Long, Corey A. Siegel, Bincy P. Abraham, Michael Chiorean, Uma Mahadevan

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Active inflammation during pregnancy in women with inflammatory bowel disease (IBD) is a risk factor for clinical relapse. 1,2 In utero exposure to biologics is not associated with adverse pregnancy outcomes 3 or infections in infants born to mothers with IBD. 1,2,4 However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero.

Original language	English (US)
Pages (from-to)	706-708.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.cgh.2021.02.003
State	Published - Mar 2022

Keywords

Child
Day Care, Medical
Female
Humans
Infant
Inflammatory Bowel Diseases/complications
Mothers
Pregnancy
Pregnancy Complications/drug therapy
Prenatal Exposure Delayed Effects/drug therapy

ASJC Scopus subject areas

Gastroenterology
Hepatology

Divisions

Gastroenterology and Hepatology

Access to Document

10.1016/j.cgh.2021.02.003

Cite this

@article{765ceef18c294adabb99ed19c6a53466,

title = "Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease",

abstract = "Active inflammation during pregnancy in women with inflammatory bowel disease (IBD) is a risk factor for clinical relapse. 1,2 In utero exposure to biologics is not associated with adverse pregnancy outcomes 3 or infections in infants born to mothers with IBD. 1,2,4 However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero. ",

keywords = "Child, Day Care, Medical, Female, Humans, Infant, Inflammatory Bowel Diseases/complications, Mothers, Pregnancy, Pregnancy Complications/drug therapy, Prenatal Exposure Delayed Effects/drug therapy",

author = "Long, \{Millie D.\} and Siegel, \{Corey A.\} and Abraham, \{Bincy P.\} and Michael Chiorean and Uma Mahadevan",

note = "Funding Information: Funding Supported by Crohn's and Colitis Foundation and National Institutes of Health (P30 DK034987). Conflicts of interest The authors disclose the following: Millie D. Long reports consulting for Takeda, Pfizer, AbbVie, UCB, Janssen, Prometheus, Salix, Valeant, and Target Pharmasolutions; and grant support from Takeda and Pfizer. Corey A. Siegel reports consulting for AbbVie, Amgen, Celgene, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Sebela, and Takeda; and grant support from AbbVie, Janssen, Pfizer, and Takeda. Bincy P. Abraham reports consulting for Pfizer, Samsung Bioepis, Medtronic, Janssen, UCB, and Takeda; research for Takeda and Janssen; and Speaker's Bureau for Janssen, UCB, AbbVie, Takeda, and Pfizer. Michael Chiorean has a relationship with Takeda, Janssen, AbbVie, Pfizer, Prometheus, Arena, Medtronic, and BMS (Bristol-Meyer-Squibb). Uma Mahadevan reports consulting for AbbVie, Janssen, Takeda, BMS, and Gilead; and research for Pfizer, Celgene, and Genentech. Funding Information: Funding Supported by Crohn{\textquoteright}s and Colitis Foundation and National Institutes of Health ( P30 DK034987 ). ",

year = "2022",

month = mar,

doi = "10.1016/j.cgh.2021.02.003",

language = "English (US)",

volume = "20",

pages = "706--708.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease

AU - Long, Millie D.

AU - Siegel, Corey A.

AU - Abraham, Bincy P.

AU - Chiorean, Michael

AU - Mahadevan, Uma

N1 - Funding Information: Funding Supported by Crohn's and Colitis Foundation and National Institutes of Health (P30 DK034987). Conflicts of interest The authors disclose the following: Millie D. Long reports consulting for Takeda, Pfizer, AbbVie, UCB, Janssen, Prometheus, Salix, Valeant, and Target Pharmasolutions; and grant support from Takeda and Pfizer. Corey A. Siegel reports consulting for AbbVie, Amgen, Celgene, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Sebela, and Takeda; and grant support from AbbVie, Janssen, Pfizer, and Takeda. Bincy P. Abraham reports consulting for Pfizer, Samsung Bioepis, Medtronic, Janssen, UCB, and Takeda; research for Takeda and Janssen; and Speaker's Bureau for Janssen, UCB, AbbVie, Takeda, and Pfizer. Michael Chiorean has a relationship with Takeda, Janssen, AbbVie, Pfizer, Prometheus, Arena, Medtronic, and BMS (Bristol-Meyer-Squibb). Uma Mahadevan reports consulting for AbbVie, Janssen, Takeda, BMS, and Gilead; and research for Pfizer, Celgene, and Genentech. Funding Information: Funding Supported by Crohn’s and Colitis Foundation and National Institutes of Health ( P30 DK034987 ).

PY - 2022/3

Y1 - 2022/3

N2 - Active inflammation during pregnancy in women with inflammatory bowel disease (IBD) is a risk factor for clinical relapse. 1,2 In utero exposure to biologics is not associated with adverse pregnancy outcomes 3 or infections in infants born to mothers with IBD. 1,2,4 However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero.

AB - Active inflammation during pregnancy in women with inflammatory bowel disease (IBD) is a risk factor for clinical relapse. 1,2 In utero exposure to biologics is not associated with adverse pregnancy outcomes 3 or infections in infants born to mothers with IBD. 1,2,4 However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero.

KW - Child

KW - Day Care, Medical

KW - Female

KW - Humans

KW - Infant

KW - Inflammatory Bowel Diseases/complications

KW - Mothers

KW - Pregnancy

KW - Pregnancy Complications/drug therapy

KW - Prenatal Exposure Delayed Effects/drug therapy

UR - https://www.scopus.com/pages/publications/85111922046

UR - https://www.scopus.com/inward/citedby.url?scp=85111922046&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2021.02.003

DO - 10.1016/j.cgh.2021.02.003

M3 - Article

C2 - 33549864

AN - SCOPUS:85111922046

SN - 1542-3565

VL - 20

SP - 706-708.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 3

ER -

Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease

Abstract

Keywords

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this